Adam Lezack - 31 Jan 2025 Form 4 Insider Report for Beta Bionics, Inc. (BBNX)

Reporting relationship: Director
Issuer ticker: BBNX
Reported as of: 31 Jan 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Feb 2025, 20:30:17 UTC
Prior SEC filing: 29 Jan 2025
Next SEC filing: 18 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Stephen Feider, Attorney-in-Fact

Key filing fact

Adam Lezack filed Form 4 for Beta Bionics, Inc. (BBNX) on 03 Feb 2025.

Key facts

This page summarizes Adam Lezack's Form 4 filing for Beta Bionics, Inc. (BBNX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Feb 2025, 20:30.

Change

Previous filing in this sequence was filed on 29 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BBNX transaction Derivative

Director Stock Option (right to buy)

Award

Transaction value: $0
Shares: +9,137
Change %
Price: $0.000000
Shares after: 9,137
Date: 31 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,137
Exercise price: $5.10
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares subject to this option shall vest in 36 equal monthly installments measured from December 12, 2023.

Footnote F2

Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock.